BIOCON LIMITED. vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of BIOCON LIMITED. (BIOCON) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads BIOCON vs TORNTPHARM on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- − ["Company has low interest coverage ratio.", "Company has a low return on equity of 3.51% over last 3 years.", "Company might be capitalizing the interest cost", "Dividend payout has been low at 10.9% of profits over last 3 years", "Promoter holding has decreased over last 3 years: -16.0%"]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 19.8 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.